Jennifer Robinson

powered by
COS Expertise®
University of Iowa
College of Public Health
Epidemiology
Associate ProfessorAppointed: 2003
University of Iowa
College of Public Health
Epidemiology
Lipid Research Clinic
Program DirectorAppointed: 2003
Foundation for Health Advocacy
FounderAppointed: 2002
Foundation for Health Advocacy
PresidentAppointed: 2002
Iowa State University
College of Human Sciences
Food Science & Human Nutrition-HS
Scientific CollaboratorAppointed: 1999

Mailing Address

SE 226 General Hospital
University of Iowa
Iowa City, Iowa 52242
United States

Contact Information

Phone: (319) 384-5004
Fax: (319) 384-5004
jennifer-g-robinson@uiowa.edu
http://www.public-health.uiowa.edu/faculty-staff/faculty/directory/faculty-detail.asp?emailAddress=jennifer-g-robinson@uiowa.edu

Qualifications

M.P.H., University of Minnesota, Epidemiology, 1995.
M.D., University of Minnesota, 1987.
B.A., Northwestern University, Political Science, 1982.

Expertise and Research Interests

My research interests include:
- Drugs affecting atherosclerosis and metabolism
- Managing cardiovascular risk factors
- Cardiovascular risk prediction
- Multilevel compliance challenge of global risk factor management
- Internet-based patient and healthcare professional education program
- Social and environmental factors affecting healthy lifestyle choices

Other Expertise

Chapters:
Davidson MH, Robinson JG. Cholesterol. In Toth P, Gotto A, eds. Prevention of High-Risk Cardiovascular Disease 2006; in press. Contribution: Literature review, interpretation, manuscript preparation (1st 2 sections on epidemiology and pathophysiology.

Future Research

Web-based education and tracking system for patients to self-manage cardiovascular risk factors.
Web-based system for healthcare providers for continuing medical education and tracking patient risk factors.

Industrial Relevance

Research into systems to improve patient adherence to cholesterol, blood pressure, and glucose-lowering medication prescriptions; as well as research into improving healthcare provider implementation of evidence-based guidelines for drug utilization for cardiovascular prevention.

Keywords

COS Keywords:

Cardiovascular System, Epidemiology, Risk Factor Analysis.

Additional Terms:

Cardiovascular Risk Prevention, Compliance, Global Risk Factor Management, Social and Environmental Factors Affecting Lifestyle Choices.

Memberships

American College of Physicians
American Heart Association
American Medical Association
American Medical Informatics Association
Iowa Medical Society
Midwest Lipid Association
National Lipid Association
Polk County Medical Society

Honors and Awards

2007, Outstanding Mentor Award, Epidemiology Student Association, College of Public Health, University of Iowa
2007, Outstanding Educator Award, Epidemiology Student Association, College of Public Health, University of Iowa
1986, Alpha Omega Alpha Honor Society,

Previous Positions

1998-2002, Guest Lecturer, Drake University, Nurse Practitioner Training Program
1998-1999, Guest Lecturer, University of Osteopathic Medicine and Health Sciences
1998-2002, Adjunct Assistant Professor, University of Iowa, College of Public Health, Epidemiology
1997-2002, Staff Physician, Mary Greeley Medical Center
1996-2002, Medical Director, Iowa Health Centers, P.C., Preventive Medicine and Research
1996-2003, Staff Physician, Broadlawns Medical Center
1996-2003, Consultant in Lipidology, Iowa Health Centers, P.C.
1996-2003, Courtesy Staff Physician, Mercy Hospital Medical Center
1994-1995, Adjunct Assistant Professor, University of Minnesota, Medical School, Kinesiology
1992-1995, Associate Director, University of Minnesota, Medical School, Heart Disease Prevention Clinic
1992-1995, Clinical Instructor, University of Minnesota, Medical Schoo
1990-1992, Staff Physician, Group Health, Inc., Internal Medicine
1987-1990, Resident, University of Minnesota, Hospitals and Clinics

Publications

  • Robinson JG (Nov 2008) LDL reduction: how low should we go and is it safe?, Current cardiology reports, 10 (6), 481-7 Abstract
  • Robinson JG, Wallace R, Limacher M, Ren H, Cochrane B, Wassertheil-Smoller S, Ockene JK, Blanchette PL, Ko MG (Sep 2008) Cardiovascular risk in women with non-specific chest pain (from the Women's Health Initiative Hormone Trials)., The American journal of cardiology, 102 (6), 693-9 Abstract
  • Hsia J, Otvos JD, Rossouw JE, Wu L, Wassertheil-Smoller S, Hendrix SL, Robinson JG, Lund B, Kuller LH, Women's Health Initiative Research Group (2008) Lipoprotein Particle Concentrations May Explain the Absence of Coronary Protection in the Women's Health Initiative Hormone Trials, Arteriosclerosis, thrombosis, and vascular biology, 9, 1666-71 Abstract
  • Robinson JG, Wallace R, Limacher M, Ren H, Cochrane B, Wassertheil-Smoller S, Ockene JK, Blanchette PL, Ko MG (Sep 2008) Cardiovascular risk in women with non-specific chest pain (from the Women's Health Initiative Hormone Trials)., The American journal of cardiology, 102 (6), 693-9 Abstract
  • Robinson JG (Apr 2008) Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk., The American journal of cardiology, 101 (7), 1009-15 Abstract
  • Robinson JG (2008) Should We Use PPAR Agonists to Reduce Cardiovascular Risk?, PPAR research, 2008, 891425 Abstract
  • Robinson JG (2007) Simvastatin: Present and future perspectives, Expert Opin, Pharmacother, 8 (13), 2159-67
  • Robinson JG, Schrott H (2007) Statin Pleiotropy: A popular concept but clinical significance unclear, Cardiovasc Drugs Ther
  • Robinson JG, Bakris G, Torner J, Stone NJ, Wallace R (2007) Is it time for a cardiovascular primary prevention trial in the elderly?, Stroke, 38 (2), 441-50
  • Robinson JG (2007) Update on PPAR Agonists: The Clinical Significance of FIELD and PROACTIVE, Curr Atheroscler Rep, 9 (1), 64-71
  • Robinson JG, Davidson M (2007) Investigational drugs targeting HDL metabolism and reverse cholesterol transport, Future Lipidolol, 2, 285-301
  • Kooperberg C, Cushman M, Hsia J, Robinson JG, Aragaki A, Baird A, Beeresford SA A, Johnson KC, Kuller L, Rodriguez B (2007) Inflammation and thrombosis biomarkers, risk of ischemic stroke, and interactions with hormone treatment in postmenopausal women, PLOS Clin Trials, 2 (6), e28
  • Jaramillo SA, Felton D, Andrews L, Desiderio L, Hallarn RK, Jackson SD, Robinson JG, Ockene JK, Coker LH, Espeland MA for the Women's Health Initiative Memory Study Research Group (2007) Enrollment in a brain magnetic resonance study: results from the Women's Health Initiative Memory Study Magnetic Resonance Imaging Study (WHIMS-MRI), Acad Radiol, 14, 603-12
  • Barter P, Gotto A, LaRosa JC, Maroni J, Szarek M, Grundy SM, Katelein JJP, Bittner V, Fruchart J-C for the Treating to New Targets Investigators (2007) HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events, N Engl J Med, 357, 1301-10
  • Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK, for Treating to New Targets Study Steering Committee and Investigators (2007) Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease, Ann Intern Med, 147, 1-0
  • Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, Kuller LH, Cochrane BB, Hunt JR, Ludlam SE, Pettinger MB, Gass M, Margolis KL, Nathan L, Ockene JK, Prentice RL, Robbins J, Stefanick ML, the WHI and WHI CACS Investigators (2007) Estrogen therapy and coronary-artery calcification, N Engl J Med, 356, 2591-602
  • Davidson MH, Robinson JG (2007) Safety considerations with aggressive lipid management, J Am Coll Cardiol, 49, 1753-62
  • Robinson JG, Wallace R, Limacher M, Sato A, Cochrane B, Wassertheil-Smoller S, Ockene JK, Blanchette PL, Ko MG (2006) Elderly women diagnosed with nonspecific chest pain may be at increased cardiovascular risk, J Womens Health, 15 (10), 1151-60
  • Robinson JG, Stone NJ (2006) Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids, Am J Cardiol, 98 (4A), 39i-49i
  • Hsia J, Manson JE, Kuller L, Pettinger M, Choe JH, Langer RD, Limacher M, Oberman A, Ockene J, O'Sullivan MJ, Robinson JG, for the Women's Health Initiative (2006) Impact of cyclooxygenase inhibitor use in the Women's Health Initiatve Hormone Trials: Secondary analysis of a randomized trial, PLOS Clin Trials, In Press
  • Robinson JG, Stone NJ (2006) Identifying patients for aggressive cholesterol lowering: The risk curve concept, Am J Cardiol, In Press
  • Davidson M, Robinson JG (2006) Lipid-lowering effects of statins: A comparative review, Exp Opin Pharmacother, 7 (13), 36-44
  • Hsia JA, Criqui MH, Herrington DM, Manson JE, Wu L, Heckbert SR, Allison M, McGrae M, Robinson JG (2006) Conjugated equine estrogens and peripheral arterial disease risk, Am J Cardiol, 152, 170-6
  • Robinson JG, Davidson MH (2006) Managing cholesterol in the elderly, Healthy Aging, 2 (4), 623-38
  • Robinson JG, Davidson M (2006) How low to target LDL-cholesterol?, Nature Clinical Practice Endocrinology & Metabolism, 2, 2-3
  • Crouse JR III, Elam MB, Robinson JG, Ambrosius WT (2006) Cholesterol Management: Targeting a Lower Low Density Lipoprotein Cholesterol Concentration Increases Adult Treatment Panel - III Goal Attainment, Am J Cardiol, 96, 1667-9
  • Robinson JG, Davidson MH (2006) Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction, Exp Rev Cardiovasc Ther, 4 (4), 461-76
  • Resnick SM, Maki PM, Rapp SR, Espeland MA, Brunner R, Coker LH, Granek IA, Hogan P, Ockene JK, for the WHISCA Investigators (2006) Coker, LH, Granek IA, Hogan P, Ockene JK, for the WHISCA Investigators. Effects of combination estrogen plus progestin hormone treatment on cognition and affect, J Clin Endocrin Metab, 19, 1802-10
  • Knopp RH, d'Emden M, Smilde JG, Pocock SJ, on behalf of the Aspen Study Group (2006) Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN), Diab Care, 29, 1478-85
  • Robinson JG, Atorvastatin in patients with type 2 diabetes mellitus undergoing dialysis., The New England Journal of Medicine, 353(17), 1858-60; author repl, Oct 2005 Abstract
  • LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets (TNT) Investigators (Apr 2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease, 352 (14), 1425-35
  • Robinson JG, Maheshwari N (Feb 2005) A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years, 95 (3), 373-8
  • Robinson JG, Smith B, Maheshwari N, Schrott H (2005) "Pleiotropic" effects of statins: Benefit beyond cholesterol reduction? A meta-regression analysis, J Am Coll Cardiol, 46, 1855-62
  • Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DS, GEMINI Investigators (Nov 2004) Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial, 292 (18), 2227-36
  • Kohatsu ND, Robinson JG, Torner JC, Evidence-based public health: an evolving concept, Am J Prev Med, 27(5), 417-21, 2004
  • Robinson JG, Conroy C, Wickemeyer WJ, Comparison of effectiveness and safety of simvastatin in patients <75 versus > or =75 years of age with coronary, cerebral, or peripheral arterial disease, The American Journal of Cardiology, 90(9), 994-5, November 2002 Abstract
  • Dent SB, Peterson CT, Brace LD, Swain JH, Reddy MB, Hanson KB, Robinson JG, Alekel DL, Soy protein intake by perimenopausal women does not affect circulating lipids and lipoproteins or coagulation and fibrinolytic factors, Journal of Nutrition, 131(9), 2280-7, September 2001 Abstract
  • St Germain A, Peterson CT, Robinson JG, Alekel DL, Isoflavone-rich or isoflavone-poor soy protein does not reduce menopausal symptoms during 24 weeks of treatment, Menopause (new York, N.y.), 8(1), 17-26, 2001 Abstract
  • Robinson JG, Boland LL, McGovern PG, Folsom AR for the ARIC Investigators, Comparison of NCEP guidelines and Framingham-based risk estimates in a population-based cohort, Prev Cardiol, 4, 148-157, 2001
  • Robinson JG, Conroy C, Wickemeyer WJ, A novel telephone-based system for management of secondary prevention to a low-density lipoprotein cholesterol < or = 100 mg/dl, The American Journal of Cardiology, 85(3), 305-8, February 2000 Abstract
  • Robinson JG, Prevention of another coronary event, Iowa Medicine, 87, 283-284, 1997
  • Robinson JG, Folsom AR, Nabulsi AA, for the ARIC Investigators, Can postmenopausal hormone replacement benefit plasma lipids in women with diabetes?, Diabetes Care, 19, 480-485, 1996
  • Robinson JG, Body fat and body image in women runners, Melpomene Inst Women Health Res, Spring, 1987

Profile Details

Last Updated: 11/21/2008

COS Expertise ID #1111547
Reference this profile directly: http://myprofile.cos.com/jgrobinson